{"id":"brivaracetam-bolus","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Behavioral changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brivaracetam binds with high affinity and selectivity to SV2A, a protein involved in synaptic vesicle trafficking and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters in the brain, thereby suppressing abnormal neuronal firing and seizure propagation. The bolus formulation provides rapid intravenous delivery for acute seizure management.","oneSentence":"Brivaracetam is a selective synaptic vesicle protein 2A (SV2A) ligand that modulates neurotransmitter release to reduce seizure activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:07.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of partial-onset seizures in patients with epilepsy"},{"name":"Acute seizure management (intravenous bolus formulation)"}]},"trialDetails":[{"nctId":"NCT03405714","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2018-06-01","conditions":"Epilepsy","enrollment":50},{"nctId":"NCT03021018","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2017-02-06","conditions":"Epilepsy","enrollment":46},{"nctId":"NCT01405508","phase":"PHASE3","title":"Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-08","conditions":"Epilepsy","enrollment":105},{"nctId":"NCT02088957","phase":"PHASE2","title":"Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures","status":"TERMINATED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-03","conditions":"Nonconvulsive Electrographic Seizures","enrollment":1},{"nctId":"NCT01796899","phase":"PHASE1","title":"Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2013-01","conditions":"Healthy Volunteers","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brivaracetam bolus","genericName":"Brivaracetam bolus","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brivaracetam is a small molecule modulator of synaptic vesicle glycoprotein 2A, classified as a drug in the MODULATOR class. It has been studied as a treatment for epilepsy, including increased seizure activity in an epilepsy monitoring unit setting, and as an intervention in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}